Work

Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Solitary plasmacytoma of bone (SPB) is a localized tumor in the bone comprised of clonal plasma cells in the absence of other diagnostic features of multiple myeloma (MM), though patients may present with <10% clonal plasma cells in the bone marrow [ 1 ]. Most patients with SPB eventually develop overt MM, and numerous factors are associated with a shorter time to progression to active MM, including the presence of high-risk cytogenetics, abnormal serum free light chain ratio, minimal marrow involvement, and high-grade angiogenesis within the plasmacytoma [ 2 , 3 , 4 , 5 ].
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W7160449753
FWCI:
Cites: 20
Cited by:
Related to: 10